Mana.bio

We were honored to be selected as an AI-driven drug discovery startup and to explore the UK ecosystem as part of this delegation. Thank you, British Embassy Israel!

We are excited to share that our Scientific Co-founder, Kira Radinsky, will be speaking at the 24th Precision Medicine World Conference (PMWC 2025), which will take place at the Santa Clara Convention Center, CA! On February 5th, Kira will participate in Track 1 (T1) on Emerging Therapeutics in a session on AI-Driven Improvements in Gene and Cell Therapy. She will share her insights on how Mana.bio is leveraging AI and machine learning technologies to optimize lipid nanoparticle (LNP) design and safety for next-generation gene therapies. If you’re attending PMWC 2025, we would love to connect and discuss how Mana.bio’s platform addresses key challenges in developing human-relevant predictions for extrahepatic LNP delivery. Learn more about the conference here: https://lnkd.in/dk2yvMDy #AI #ML #TechBio #LNP #UnlockDelivery #GeneDelivery #GeneTherapy #PMWC25 PMWC - Precision Medicine World Conference

News Update: We’re thrilled to announce groundbreaking advancements in systemic LNP tolerability and targeted RNA delivery powered by our novel AI-driven safety model. We presented our findings yesterday at the 3rd annual LNP Immunogenicity & Toxicity Summit in Boston hosted by Hanson Wade. These achievements highlight the immense potential of integrating AI and ML into LNP design, paving the way for safer and more effective RNA therapies. #AI #ML #RNA #LNP #Biotech https://lnkd.in/dEHKGGBQ

Our CEO, Yogev Debbi, is speaking next week at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston, MA. Join us for his presentation on Tuesday, December 10, at 9:30 AM, where he’ll share Mana.bio’s groundbreaking advancements in LNP safety, potency, and targeting for gene therapies. We’re excited to keep pushing towards unlocking RNA delivery and to accelerate development of therapeutics for patients. #LNP #DrugDelivery #GeneTherapy #Techbio #AI

Thank you to everyone who joined our CEO, Yogev Debbi, at the 14th annual #PODDConference Conference in Boston! It was a great opportunity to share Mana.bio's AI-driven approach to advancing drug delivery with our LNP technology. Looking forward to the collaborations ahead as we work together to shape the future of genetic medicine delivery! #PODD

A First in Rare Disease Genetics: Emma’s Story and the Untapped Power of ‘Junk DNA’ Emma Broadbent's groundbreaking diagnosis as the first patient with a disorder caused by CHASERR lncRNA deletion showcases the profound potential of exploring non-coding DNA. Her story underscores the importance of these "genomic dark regions" in rare disease diagnosis. Join us at PMWC 2025 in the CGT in Rare Disease Track (Feb. 5-7) to delve into the latest advancements in rare disease research: ~Keynote: Bioorthogonal Chemistry, from Basic Science to Clinical Translation Carolyn Bertozzi, Stanford ~Keynote: The Promise of Genetic Medicines Unless You're Too Poor or Too Rare- James M. Wilson, GEMMA Biotherapeutics ~Addressing Ethical and Financial Barriers in Gene Therapy Chair: Tim Hunt, Alliance for Regenerative Medicine ~Next-Generation Delivery Systems for Gene Therapies Chair: Morten Sogaard, Astellas Gene Therapies Panelists: Mathieu Nonnenmacher (Voyager Therapeutics, Inc.), Kevin Friedman (Kelonia Therapeutics), Kunwoo Lee (GenEdit), Haig Aghajanian (Capstan Therapeutics) ~Beyond the Genome: Harnessing Epigenetics in Rare Disease Treatment Chair: Charles Gersbach, Duke Panelists: Prashant Mali, (UCSD), Nadav Ahituv (UCSF), Blythe Sather (Tune Therapeutics), Fyodor Urnov (Berkeley University) ~Navigating the Regulatory Landscape for Gene and Cell Therapies Chair: Yael Weiss, Mahzi Therapeutics Panelists: Courtney Silverthorn (BGTC), Peter Marks (FDA), Benjamin Dewees (Kyverna Therapeutics) ~AI-driven Improvements in Gene and Cell Therapy Chair: Morten Sogaard, Astellas Panelists: Francois Vigneault (Shape Therapeutics Inc.), John Androsavich (Ginkgo Bioworks, Inc.), Yogev Debbi (Mana.bio) See program: https://lnkd.in/gPtkWZbQ Emma's story by BioQuick News- https://shorturl.at/LEMcc PMWC - Precision Medicine World Conference, Mike O'Neill #PMWC2025 #RareDiseases #PrecisionMedicine #Genomics #HealthcareInnovation #GeneticResearch #NonCodingDNA #RareDiseaseAwareness #GenomicInnovation #GeneTherapy #PersonalizedMedicine

Our CEO Yogev Debbi is speaking next week at the 14th annual #PODD - Partnership Opportunities In Drug Delivery Conference in Boston. Stop by to see our company presentation on Tuesday, October 29th during the Soapbox Presentations from 11:55-12:40 pm ET.

Our dear Scientific Co-founder Kira Radinsky was interviewed to Crafted. and shared her opinion on AI, how we use it at Mana and the future potential of AI in life science. Excited to have such amazing team members with us, on our mission to unlock RNA delivery with our programmable AI platform. Links to listen below

News Update: Our team has signed a collaborative research agreement with Sheba Medical Center, Tel Hashomer. Through this study we plan to utilize our programmable AI platform to enhance personalized medicine by using RNA delivery to reprogram T-cells in the fight against challenging diseases such as cancer and autoimmune disorders. We are excited to be working with Sheba Medical Center on such a novel study to push the boundaries of RNA delivery. Our AI based programmable platform enables the discovery of efficient, safe, more precise delivery formulations - providing us the opportunity to unlock the full potential of RNA therapies across a wide range of disease areas. https://lnkd.in/dHueK-yU #RNA #LNP #AI

We’ve been recognized by TheMarker as one of the Top 20 promising start-ups in Israel alongside PhaseV, Protai, caVos Biotherapeutics, and more. This is a testament to the resilience of our community - so many exciting ideas becoming a reality. You can read the full piece here: https://lnkd.in/dmQpZQQH